Clinicopathological, prognostic and predictive value of CD166 expression in colorectal cancer: a meta-analysis.

摘要: // Susu Han 1,* , Wei Yang Shaoqi Zong 1 Hongjia Li Shanshan Liu Wen Qi Shi and Fenggang Hou Oncology Department of Shanghai Municipal Hospital Traditional Chinese Medicine, TCM University, Shanghai, People’s Republic China * Co-first authors Correspondence to: Hou, email: Shi, Keywords : CD166, expression, CRC, survival, clinical features Received December 28, 2016 Accepted March 13, 2017 Published April 26, Abstract CD166 has been identified as an important cancer stem cell (CSC) marker in colorectal (CRC). The purpose our study was to investigate the relationship between expression examine role on survival patients with CRC. A total 15 studies 3,332 cases were this meta-analysis. pooled OR indicated that significantly higher CRC than colonic adenomas or normal mucosa (OR = 3.48, P 0.002 55.13, 0.017, respectively). found be negatively correlated vascular invasion 0.75, 0.017), but it not associated gender, tumor location, lymph node status, distant metastasis, stage, T classification differentiation. Meanwhile, prognosis overall (OS) (HR 1.20, 95% CI 0.45-3.22, 0.72) multivariate regression analysis. One reported may a predictor stage II using logistic analysis (OS: 9.97, 0.035; disease-specific survival: 29.02, 0.011). Our findings suggest carcinogenesis decreased risk invasion, become predictive biomarker for patients, additional large sample sizes are essential validate prognostic values expression.